277 related articles for article (PubMed ID: 21282357)
1. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
Cen O; Longnecker R
Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
[TBL] [Abstract][Full Text] [Related]
2. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
[TBL] [Abstract][Full Text] [Related]
3. Two Pathways of p27
Sora RP; Ikeda M; Longnecker R
mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.
Dargart JL; Fish K; Gordon LI; Longnecker R; Cen O
Antiviral Res; 2012 Jul; 95(1):49-56. PubMed ID: 22609829
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
Bieging KT; Swanson-Mungerson M; Amick AC; Longnecker R
Cell Cycle; 2010 Mar; 9(5):901-8. PubMed ID: 20160479
[TBL] [Abstract][Full Text] [Related]
6. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
Perez-Chacon G; de Los Rios C; Zapata JM
Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
[TBL] [Abstract][Full Text] [Related]
7. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
Ikeda M; Hayes CK; Schaller SJ; Longnecker R
Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
Bieging KT; Amick AC; Longnecker R
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507
[TBL] [Abstract][Full Text] [Related]
9. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
Pang MF; Lin KW; Peh SC
Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
[TBL] [Abstract][Full Text] [Related]
10. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
Fish K; Chen J; Longnecker R
Blood; 2014 Jan; 123(4):530-40. PubMed ID: 24174629
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
Bultema R; Longnecker R; Swanson-Mungerson M
Oncogene; 2009 Mar; 28(11):1471-6. PubMed ID: 19182823
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus (EBV) genomes and c-myc oncogene in oral Burkitt's lymphomas.
Syrjänen S; Kallio P; Sainio P; Fuju C; Syrjänen K
Scand J Dent Res; 1992 Jun; 100(3):176-80. PubMed ID: 1321486
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) Enhances ATP Production in B Cell Tumors through mTOR and HIF-1α.
Incrocci R; Monroy Del Toro R; Devitt G; Salimian M; Braich K; Swanson-Mungerson M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612754
[TBL] [Abstract][Full Text] [Related]
17. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?
Allday MJ
Semin Cancer Biol; 2009 Dec; 19(6):366-76. PubMed ID: 19635566
[TBL] [Abstract][Full Text] [Related]
18. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
19. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
20. [Epstein-Barr virus and Burkitt's lymphoma].
Joab I
Med Trop (Mars); 1999; 59(4 Pt 2):499-502. PubMed ID: 10901854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]